# Colossal Biosciences Reportedly in Talks to Raise New Capital at $20B-$30B Valuation

> **Platform:** [SPIDITS AI](https://spidits.com/) — Real-Time AI News & Market Intelligence  
> **Published:** 2026-07-20T23:39:35.000Z  
> **Category:** FUNDING  
> **Impact Score:** 180/100  
> **Primary Source:** [TechCrunch Startups](https://techcrunch.com/2026/07/20/colossal-biosciences-reportedly-in-talks-to-raise-new-capital-at-20b-30b-valuation)  
> **Canonical Citation:** [https://spidits.com/timeline/colossal-biosciences-reportedly-in-talks-to-raise-new-capital-at-20b-30b](https://spidits.com/timeline/colossal-biosciences-reportedly-in-talks-to-raise-new-capital-at-20b-30b)

## Executive Summary
The de-extinction startup is looking to double or triple its previous valuation, according to the report.

## Why It Matters (Strategic Analysis)
This staggering valuation surge reflects a structural industry pivot toward deep-tech commercialization where synthetic biology merges with artificial intelligence. Crucially, this shifts biological engineering from pure academic research into high-margin enterprise software and sustainable markets.

## Referenced Coverage & Sources
- **[TechCrunch Startups](https://techcrunch.com/2026/07/20/colossal-biosciences-reportedly-in-talks-to-raise-new-capital-at-20b-30b-valuation)**: Colossal Biosciences reportedly in talks to raise new capital at $20B-$30B valuation — _The de-extinction startup is looking to double or triple its previous valuation, according to the report._

---
*Synthesized by SPIDITS AI Market Intelligence Desk. Track live AI news, model releases, and funding: [https://spidits.com](https://spidits.com)*